Cellmid close to royalties on cancer test licences
26 March, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) has provided an update on the two cancer diagnostics tests under development by its licensees using midkines as a biomarker.
Viralytics CEO hails cancer virotherapy milestone
22 March, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) CEO Dr Malcolm McColl has called the news that Amgen met its goal with an oncolytic virus trial a “milestone event for the field.”
Prima to get $4.7m grant for cancer vaccine
21 March, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) will receive a $4.7m grant from Saxony Development Bank and will use the funds to explore the use of CVac in more cancer types beyond ovarian.
Patrys cancer antibody synergistic in myeloma
21 March, 2013 by Dylan Bushell-EmblingAnimal trials of Patrys’s (ASX:PAB) anticancer antibody PAT-SM6 suggest the treatment is more effective when combined with other multiple myeloma treatments.
New treatment effective for chronic pain
20 March, 2013A new device that stimulates the spinal cord provides relief for patients with difficult-to-treat chronic pain.
Biolife signs cancer vaccine manufacturing deal
19 March, 2013 by Dylan Bushell-EmblingBiolife Science has signed on Pevion Biotech to manufacture its HER-Vaxx anticancer vaccine in preparation for phase II trials in gastric cancer.
Emerging drug resistance in young malaria parasites
18 March, 2013 by Susan WilliamsonThe alarming rate at which the malaria parasite is developing resistance to drugs may be countered by changing the timing of the drug treatment and developing drugs that last longer in the bloodstream.
NHMRC Ethics Award
14 March, 2013 by Susan WilliamsonNominations for the NHMRC 2013 Ethics Award close on 22 March 2013.
Biolife Science $5m ASX listing to progress cancer vaccine
14 March, 2013 by Susan WilliamsonAustralian shareholders are being given the opportunity to buy into Biolife Science with a vaccine that shows potential to combat stomach (gastric) and breast cancer.
Robots play role in dementia treatment
11 March, 2013 by Susan WilliamsonProving the benefits and cost-effectiveness of animal robots in the treatment of dementia is the focus of a Griffith research study.
Anti-ageing protein linked to pancreatic cancer
06 February, 2013 by Tim DeanSirtuin, which is known for its link to ageing, has been associated with pancreatic cancer, raising the prospect of new treatments.
Discovery paves way for new gastric cancer treatment
17 January, 2013 by Tim DeanDrugs that inhibit a protein involved in the growth of colon and gastric cancers could be developed into a new treatment.
Insulin’s molecular handshake caught in the act
10 January, 2013 by Tim DeanResearchers at WEHI have used the Australian Synchrotron to generate the world’s first 3D images of insulin docking with cells, a finding that could lead to improved treatments for diabetes.
BioDiem partner close to filing for vaccine exports
12 December, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) partner Serum Institute of India will file for WHO approval in early 2013 to export flu vaccines based on BioDiem's LAIV platform.
Patrys (ASX:PAB) hits myeloma trial milestone
10 December, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed the main round of dosing for the first three patients enrolled in a German trial of its PAT-SM6 antibody in multiple myeloma.
